Convection-enhanced delivery of nanocarriers for the treatment of brain tumors

Allard, Émilie; Passirani, Catherine; Benoit, Jean‐Pierre

doi:10.1016/j.biomaterials.2009.01.003

Cited by 266 publications

(255 citation statements)

References 144 publications

(212 reference statements)

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…In recent years, superparamagnetic iron oxide nanoparticles have shown great potential applications in many biological fields, including targeteddrug delivery [1,2], bioseparation [3], tissue repair [4], cancer treatment through hyperthermia [5,6], and magnetic resonance imaging (MRI) contrast enhancement [7][8][9]. MRI is an appealing noninvasive approach for early cancer diagnostics and therapeutics [10].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Arsalani¹,

Fattahi²,

Nazarpoor³

2010

Express Polym. Lett.

236

View full text Add to dashboard Cite

Abstract. The magnetite (Fe3O4) nanoparticles (MNPs) coated with poly(N-vinyl pyrrolidone) (PVP) via covalent bonds were prepared as T2 contrast agent for magnetic resonance imaging (MRI). The surface of MNPs was first coated with 3-(trimethoxysilyl) propyl methacrylate (silan A) by a silanization reaction to introduce reactive vinyl groups onto the surface, then poly(N-vinyl pyrrolidone) was grafted onto the surface of modified-MNPs via surface-initiated radical polymerization. The obtained nanoparticles were characterized by FT-IR (Fourier transform infrared spectroscopy), XRD (X-ray diffraction), TEM (transmission electron microscopy), VSM (vibrating sample magnetometer), and TGA (thermogravimetric analysis). The MNPs had an average size of 14 nm and exhibited superparamagnetism and high saturation magnetization at room temperature. T2-weighted MRI images of PVP-grafted MNPs showed that the magnetic resonance signal is enhanced significantly with increasing nanoparticle concentration in water. The r1 and r2 values per millimole Fe, and r2/r1 value of the PVP-grafted MNPs were calculated to be 2.6 , 72.1, and 28.1(mmol/l) -1 ·s -1 , respectively. These results indicate that the PVP-grafted MNPs have great potential for application in MRI as a T2 contrast agent. Vol.4, No.6 (2010) 329-338 Available online at www.expresspolymlett.com DOI: 10.3144/expresspolymlett.2010.42 region that they are accumulated, and hence cause negative contrast and provide a dark state in the image where the compounds are accumulated [15]. However, the direct use of magnetic nanoparticles as in vivo MRI contrast agent results in biofouling of the particles in blood plasma and formation of aggregates that are quickly sequestered by cells of the reticular endothelial system (RES) such as macrophages [16,17]. Furthermore, aggregated nanoparticles change their superparamagnetic response [7]. Therefore, in order to minimize biofouling and aggregation of particles and escape from the RES for longer circulation times, the nanoparticles are usually coated with a layer of hydrophilic and biocompatible polymer such as dextran [18], dendrimers [19], poly(ethylene glycol) (PEG) [20], and poly(vinyl pyrrolidone) (PVP) [21][22][23]. Of synthetic polymers, PVP is water-soluble, non-charged, non-toxic, and is used in various medical applications [24]. While there is a potential concern about covalent interaction between hydrophilic polymers and magnetic nanoparticles in order to increase their stability in physiological medium [25][26][27][28][29], PVP coating on Fe 3 O 4 nanoparticles in all previous works has been achieved through noncovalent interaction. Now, polymers grafting of magnetic nanoparticles is one of the most attractive methods of surface modification [30,31]. In the present study, we carried out chemical synthesis and characterization of PVP-functionalized magnetite (Fe 3 O 4 ) nanoparticles. Since the PVP was bonded to the surface of magnetite nanoparticles through covalent bonds, the prepared magnetic fluid (ferrofluid) was ve...

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Arsalani¹,

Fattahi²,

Nazarpoor³

2010

Express Polym. Lett.

236

View full text Add to dashboard Cite

show abstract

“…Magnetic nanoparticles (MNPs) have attracted great attention because of their unique physical and chemical properties and their potential in various biomedical applications, such as contrast agents, carriers for drug delivery, the magnetic separation in microbiology, biochemical sensing, (1) deoxyribo nucleic acid (DNA) and ribo nucleic acid (RNA) purification, cell separation, (2)(3)(4) targeted drug delivery, (5,6) separation, (7) tissue repair, (8) cancer treatment through hyperthermia, (9,10) and magnetic resonance imaging (MRI) contrast enhancement. (11)(12)(13) MRI is an appealing noninvasive approach for early cancer diagnosis and therapeutics.…”

Section: Introductionmentioning

confidence: 99%

Particle Size Determination and Magnetic Characterization of Fe3O4 Nanoparticles Using Superconducting Quantum Interference Device Magnetometry

2016

Sensors and Materials

View full text Add to dashboard Cite

Magnetic nanoparticles (MNPs) were synthesized by a chemical co-precipitation method, which produces monodisperse, nanosize, benign superparamagetic iron oxide nanoparticles (SPIONs) at a reduced synthesis temperature. The crystal structure, morphology, and magnetic characterization were determined by X-ray diffraction (XRD), transmission electron microscopy (TEM), and superconducting quantum interference device (SQUID) magnetometer, respectively. The XRD pattern shows that the presence of the most intense peak corresponds to the (311) crystallographic orientation of the spinel phase of Fe 3 O 4 MNPs. The crystallite size of 4-6 nm was determined from the XRD pattern by using the Scherrer approximation. A TEM image of the MNP showed the mean diameter of 18 ± 10 nm. Magnetization versus temperature (M-T) curve values were used to determine the blocking temperature and particle size by Néel-Arrhenius law and magnetization versus magnetic field (M-H) curve values were used to calculate the size of magnetic particles by the Langevin equation. The particle sizes were found to be 19 and 10 nm. The MNPs proved to be superparamagnetic by M-H characterization at 10 and 300 K.

show abstract

“…CED can likewise deliver nanocarriers loaded with antineoplastic agents for CNS tumor therapy [26]. When combined with CED, the encapsulation of the drug infused into nanocarriers further reduces the potential side effects caused by drug leakage, while extends the brain New Approaches to the Management of Primary and Secondary CNS Tumorshalf-life of anticancer agents by preventing them from being rapidly metabolized and/or eliminated by capillaries from the injection site.…”

mentioning

confidence: 99%

Managing CNS Tumors: The Nanomedicine Approach

Aparicio-Blanco¹,

Torres-Suárez²

2017

New Approaches to the Management of Primary and Secondary CNS Tumors

View full text Add to dashboard Cite

Albeit the rapidly evolving knowledge about tumor biochemistry enables various new drug molecules to be designed as treatments, malignant central nervous system (CNS) tumors remain untreatable due to the failure to expose the entire tumor to such therapeutics at pharmacologically meaningful quantities. Therefore, drug delivery in CNS tumors must be properly addressed, as otherwise, novel therapies will continue to fail. In this regard, nanomedicine poses an appealing platform for efficient drug delivery to the CNS, since it may be targeted to improve the drug availability in the site of action, which would be translated into lower drug doses and fewer side effects. Hence, the accumulation of data about the CNS physiology and their relevant receptors, the widening therapeutic armamentarium of drugs potentially useful in CNS chemotherapy and the alternative routes for administration may envisage nanomedicines as a forthcoming routine approach. Indeed, on the basis of the promising results gathered from preclinical studies of nanomedicine-based therapy both systemically and locally administered, some nanomedicines have already been approved for clinical trials in a variety of CNS tumor conditions to serve as the first steps in the translation of nanotherapy to clinic. Their outcome will steer research directions for further improvements.

show abstract

Convection-enhanced delivery of nanocarriers for the treatment of brain tumors

Cited by 266 publications

References 144 publications

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Particle Size Determination and Magnetic Characterization of Fe3O4 Nanoparticles Using Superconducting Quantum Interference Device Magnetometry

Managing CNS Tumors: The Nanomedicine Approach

Contact Info

Product

Resources

About